BioStem Technologies to Present at the 16th Annual LD Micro Invitational

Rhea-AI Summary

BioStem Technologies (OTC:BSEM) announced that company management will present at the 16th Annual LD Micro Invitational in Los Angeles, CA.

The presentation is scheduled for Monday, May 18, 2026, at 1:30 PM ET, with live and archived webcasts available on the company’s investor relations website.

AI-generated analysis. Not financial advice.

News Market Reaction – BSEM

+2.11%

1 alert

+2.11% News Effect

On the day this news was published, BSEM gained 2.11%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

POMPANO BEACH, Fla., May 12, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the 16^th Annual LD Micro Invitational in Los Angeles, CA.

BioStem’s management is scheduled to present on Monday, May 18, 2026, at 1:30 PM ET. Interested parties may access live and archived webcasts of the presentations on the “investors” section of the Company’s website at: ir.biostemtechnologies.com.

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain^®, CryoTek^® and SteriTek^® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). BioStem’s portfolio of quality brands includes its Neox^®, Clarix^®, VENDAJE^® and American Amnion™ product lines.

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin
Group E-Mail: ir@biostemtech.com

Public Relations:
Jennifer Horton, Relevance
jennifer@relevance.com

FAQ

When will BioStem Technologies (OTC:BSEM) present at the 16th Annual LD Micro Invitational?

BioStem Technologies management will present on Monday, May 18, 2026, at 1:30 PM ET. The presentation is part of the 16th Annual LD Micro Invitational in Los Angeles, offering investors direct insight into the company’s regenerative medicine business.

How can investors access the BioStem Technologies (OTC:BSEM) LD Micro Invitational webcast?

Investors can access live and archived webcasts through the investors section of BioStem Technologies’ website. According to the company, the webcast will be available at ir.biostemtechnologies.com for those unable to attend the conference in person.

Where is the BioStem Technologies (OTC:BSEM) presentation for the LD Micro Invitational being held?

The BioStem Technologies presentation will take place in Los Angeles, California, during the 16th Annual LD Micro Invitational. According to the company, management will present to investors and interested parties, with simultaneous online access via the investor relations website.

What type of company is BioStem Technologies (OTC:BSEM) presenting at the LD Micro Invitational?

BioStem Technologies is described as a regenerative medicine company focused on perinatal tissue allograft products. The firm develops, manufactures, and commercializes these products, and its LD Micro Invitational presentation allows investors to learn more about its business model and strategy.

Why might BioStem Technologies’ (OTC:BSEM) LD Micro Invitational presentation matter to shareholders?

The presentation offers shareholders a chance to hear directly from BioStem Technologies’ management about its perinatal tissue allograft business. According to the company, the webcast format ensures broad access for both current and potential investors following the OTC-listed stock.